📊 INDP Key Takeaways
Is Indaptus Therapeutics, Inc. (INDP) a Good Investment?
Indaptus Therapeutics is a pre-revenue biotech company with severe cash burn and deteriorating financial health. The company is consuming ~$14.8M in operating cash annually while generating no revenue, with only 8.5M in cash reserves providing roughly 6-7 months of runway at current burn rates. Without demonstrated clinical progress or revenue generation, the company faces imminent liquidity challenges and shareholder dilution.
Indaptus Therapeutics appears to be a pre-revenue clinical-stage biotech with no commercial revenue, persistent operating losses, and deeply negative returns on equity and assets. While the balance sheet has no long-term debt and still holds cash, the current cash balance is materially below the recent annual operating cash burn, implying meaningful financing risk and weak growth quality unless clinical progress materially improves funding access or operating efficiency.
Why Buy Indaptus Therapeutics, Inc. Stock? INDP Key Strengths
- Positive current ratio of 1.51x indicates short-term liquidity capacity above minimum thresholds
- Minimal long-term debt obligations reduces leverage risk
- Substantial cash position of 8.5M provides near-term operational runway
- Debt-free capital structure reduces financial leverage risk
- Cash represents the majority of total assets, providing near-term operating flexibility
- Net loss and diluted EPS improved year over year, indicating some expense moderation
INDP Stock Risks: Indaptus Therapeutics, Inc. Investment Risks
- Zero revenue with -19.8M operating loss indicates non-viable business model at present stage
- Annual operating cash burn of -14.8M will exhaust 8.5M cash reserves within 6-7 months without funding
- Negative ROE of -661.5% and ROA of -223.9% demonstrate severe capital inefficiency
- Net loss deteriorated 38.8% YoY indicating worsening financial trajectory
- No disclosed long-term debt suggests future capital raises will require significant equity dilution
- 9 Form 4 insider filings in 90 days may signal uncertainty or opportunistic trading during distress
- No revenue base means the business is entirely dependent on external financing and pipeline execution
- Operating cash outflow materially exceeds cash on hand, creating elevated dilution or capital raise risk
- Very low equity base and extremely negative ROE/ROA reflect weak underlying financial sustainability
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Clinical trial progress and FDA milestone achievements
- Pipeline advancement and partnership announcements
- Capital raise activities and dilution impact on shareholder equity
- Operating expense reduction initiatives
- Quarterly operating cash burn relative to cash and equivalents
- Clinical pipeline milestones and any resulting revenue partnerships or non-dilutive funding
Indaptus Therapeutics, Inc. (INDP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Indaptus Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
INDP Profit Margin, ROE & Profitability Analysis
INDP vs Healthcare Sector: How Indaptus Therapeutics, Inc. Compares
How Indaptus Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Indaptus Therapeutics, Inc. Stock Overvalued? INDP Valuation Analysis 2026
Based on fundamental analysis, Indaptus Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Indaptus Therapeutics, Inc. Balance Sheet: INDP Debt, Cash & Liquidity
INDP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Indaptus Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-44.96 indicates the company is currently unprofitable.
INDP Revenue Growth, EPS Growth & YoY Performance
Indaptus Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
INDP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Indaptus Therapeutics, Inc. (CIK: 0001857044)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INDP
What is the AI rating for INDP?
Indaptus Therapeutics, Inc. (INDP) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INDP's key strengths?
Claude: Positive current ratio of 1.51x indicates short-term liquidity capacity above minimum thresholds. Minimal long-term debt obligations reduces leverage risk. ChatGPT: Debt-free capital structure reduces financial leverage risk. Cash represents the majority of total assets, providing near-term operating flexibility.
What are the risks of investing in INDP?
Claude: Zero revenue with -19.8M operating loss indicates non-viable business model at present stage. Annual operating cash burn of -14.8M will exhaust 8.5M cash reserves within 6-7 months without funding. ChatGPT: No revenue base means the business is entirely dependent on external financing and pipeline execution. Operating cash outflow materially exceeds cash on hand, creating elevated dilution or capital raise risk.
What is INDP's revenue and growth?
Indaptus Therapeutics, Inc. reported revenue of N/A.
Does INDP pay dividends?
Indaptus Therapeutics, Inc. does not currently pay dividends.
Where can I find INDP SEC filings?
Official SEC filings for Indaptus Therapeutics, Inc. (CIK: 0001857044) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INDP's EPS?
Indaptus Therapeutics, Inc. has a diluted EPS of $-21.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INDP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Indaptus Therapeutics, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INDP stock overvalued or undervalued?
Valuation metrics for INDP: ROE of -661.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INDP stock in 2026?
Our dual AI analysis gives Indaptus Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INDP's free cash flow?
Indaptus Therapeutics, Inc.'s operating cash flow is $-14.8M, with capital expenditures of $3.9K.
How does INDP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -661.5% (avg: 15%), current ratio 1.51 (avg: 2).